About
The Nasodine Story
Nasodine® Nasal Spray is the product of more than 10 years of pharmaceutical R&D by Firebrick Pharma Ltd, an innovative Australian biopharmaceutical company.
Nasodine Nasal Spray has been assessed in multiple independently-controlled human clinical trials. These trials show that Nasodine Nasal Spray is safe to use as recommended and support its effective use in a range of clinical settings.
Nasodine Nasal Spray is backed by a growing list of peer-reviewed publications that are publicly available for review (see below).
Firebrick Pharma owns multiple international patents on Nasodine Nasal Spray. The Nasodine® trademark is an internationally registered trademark owned by Firebrick Pharma.
In January 2026, Firebrick introduced in Singapore the first new addition to the Nasodine range: Nasodine Throat Spray, a 1% povidone-iodine formulation specifically designed for killing germs in the throat.

Firebrick Pharma co-founders Dr Stephen Goodall and Dr Peter Molloy
Peer-reviewed Publications on Nasodine Nasal Spray:
1. Polasek, T. M., & Friedland, P. L. (2025). Povidone-iodine nasal spray (Nasodine®) for the common cold: a randomized, controlled, double-blind, Phase III clinical trial. Frontiers in Medicine,12, 1565069. DOI:10.3389/fmed.2025.1565069 https://pubmed.ncbi.nlm.nih.gov/40538402
2. Friedland, P. L., & Tucker, S. (2024). Phase II Trial of the Impact 0.5% Povidone‐Iodine Nasal Spray (Nasodine®) on Shedding of SARS‐CoV‐2. The Laryngoscope, 134(9), 3947-3952. DOI:10.1002/lary.31430 https://pubmed.ncbi.nlm.nih.gov/38554057
3. Friedland, P. L., Polasek, T. M., & Topliss, D. (2024). Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone‐iodine nasal spray (Nasodine). In International Forum of Allergy & Rhinology (Vol. 14, No. 9). DOI:10.1002/alr.23389 https://pubmed.ncbi.nlm.nih.gov/38869489
4. Hale, S. J. et al. (2023). In vitro Nasodine can be an effective antibiofilm agent for biofilms that may cause CRS. The Laryngoscope, 133(10), 2490-2495. https://doi.org/10.1002/lary.30558
5. Friedland, P. et al. (2022). In vivo (human) and in vitro inactivation of SARS-CoV-2 with 0.5% povidone-iodine nasal spray. Australian Journal of Otolaryngology. 2022, 5, (0), pp. 1-9 https://www.theajo.com/article/view/4466/html
6. Ramezanpour, M. et al. (2020). In vitro safety evaluation of a povidone‐iodine solution applied to human nasal epithelial cells. InInternational forum of allergy & rhinology(Vol. 10, No. 10, pp. 1141-1148). https://doi.org/10.1002/alr.22575
Nasodine Nasal Spray is your confident choice for eliminating germs in the nasal passages
Power of povidone-iodine in a nasal spray
Shown in laboratory studies to kill all the germs that can cause nasal infections.
Commuting and crowds may be hotspots for germs
When people around you have symptoms, Nasodine can help protect you from other people's germs.
The right choice for healthcare professionals
Backed by 10 years of R&D, proven clinical safety, and published clinical studies.